HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Featured / Express Scripts Formulary Has Hep C, MS Exclusions

Express Scripts Formulary Has Hep C, MS Exclusions

Express Scripts adopted a more aggressive strategy in its 2019 formulary, excluding products for HIV, multiple sclerosis and Factor VIII, and swapping a key hepatitis C drug with a reportedly less-effective treatment.

According to a Drug Channels blog post, the formulary excluded AbbVie’s Mavyret in favor of Merck’s Zepatier. Mavyret, which carries a low list price, is the “market share leader,” while Zepatier’s price was recently cut, but is unable to treat all types of hep C.

“Consequently, the 2019 preferred formulary will force at least one in four patients to use the products with high list prices and high rebates,” Drug Channels’ Adam Fein writes. “Many patients will end up incurring much higher out-of-pocket costs.”

Below are exclusions and inclusions in key specialty categories, according to the post:

Multiple sclerosis

  • Exclusion: Extavia
  • Inclusions: Avonex, Betaseron, Plegridy, Rebif and Rebif Rebidose

HIV antiretrovirals

  • Exclusion: Atripla
  • Inclusions: Biktarvy, Genvoya, Odefsey, Stribild, Symfi, Symfi Lo and Triumeq

Factor VIII recombinant

  • Exclusions: Eloctate, Recombinate, Xyntha and Solofuse
  • Inclusions: Advate, Adynovate, Afstyla, Helixate Fs, Kogenate FS, Kovaltry, Novoeight and Nuwiq.

Click here to read the full blog post on the Drug Channels.



You might also be interested in:

  • Addressing the Affordability Crisis of Cell & Gene Therapies 12/16/2020
  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • Trump's "Buy American" Executive Order Could Raise Drug Prices 08/06/2020
  • [Webinar] How can VA/HTA Inform Policy Interventions and… 10/15/2020
  • Patient Drug Costs Increased as Health Plans Promote… 08/07/2020
  • Stanford Center for Health Education Launches Online Program… 08/11/2020
  • ICER Signs Multi-Year Deal to Use New Cloud-Based Analytic… 02/20/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • The HEOR & RWE Marketplace
    • Visit the Market Place
    • On-demand Webinar
  • Industry Events
    • 5 Tips for Trade Show Success
    • HE Innovation Webinar
    • Webinar Services from HealthEconomics.Com
    • View Conferences
    • View Webinars
    • View Webinar Archives
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute